Navigation Links
Novartis to Expand Global Research Headquarters in Cambridge, MA

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Novartis announced today that it will add 300 new jobs and invest $600 million over the next five years to expand its global Research headquarters campus on Massachusetts Avenue in Cambridge, Mass.  

"Novartis was the first global pharmaceutical company to move its Research headquarters to Massachusetts just a few years ago.  It has achieved prominence and, we believe, helped to amplify Cambridge's magnetism for others in the biomedical field to follow," said Mark Fishman, President of the Novartis Institutes for BioMedical Research.  "Our scientists and physicians here already have discovered a host of new medicines, and established fruitful collaborations with academic, clinical, and biotech institutions.  The constellation of talent and environment are unmatched.  We look forward to the next wave of new medicines coming from this center."

The company plans to expand its current Massachusetts Avenue campus, adjacent to MIT, by more than 400,000 square feet, including laboratory, office and retail space. Construction is expected to begin in 2011.

"Novartis' commitment to expand and create more jobs in Massachusetts is an affirmation of the Commonwealth's international leadership and investments in the life sciences," said Governor Deval Patrick. "As one of the key drivers of our innovation economy, Novartis' new plan to create jobs and invest in Massachusetts offers proof that businesses are growing here and our economy is on the move."

The new campus will be built on a four-acre parcel that Novartis is leasing from MIT under an expanded agreement originally signed in 2009.

"Novartis is a life sciences leader and exemplary corporate citizen in Cambridge," said Cambridge Mayor David Maher. "This is a global company that acts locally through a wide variety of programs in our community.  Their decision to grow here is great news for Cambridge and a testament to the dynamic life sciences climate here."

Since 2002 Novartis has steadily grown its operations in Cambridge. Today the company employs more than 2,000 associates and occupies more than 1 million square feet of laboratory and office space -- making it the city's largest corporate employer.  The company's operations in Cambridge include the global headquarters for the Novartis Institutes for BioMedical Research; Novartis Molecular Diagnostics, a dedicated business unit focused on developing tests to advance patient tailored treatment; Novartis Vaccines and Diagnostics, a division focused on providing vaccines and diagnostic tools to prevent diseases and protect societies worldwide, and the U.S. office of the Novartis Venture Funds.

DisclaimerThe foregoing release contains forward-looking statements that can be identified by terminology such as "to expand," "will," "expected," "look forward to," "plans," "commitment," or similar expressions, or by express or implied discussions regarding potential future approvals of new medicines developed or to be developed by the Novartis Institutes for BioMedical Research, or regarding potential future revenues from such medicines. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new medicines developed or to be developed by the Novartis Institutes for BioMedical Research will be submitted or approved for sale in any market. Nor can there be any guarantee that any such medicines will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these medicines could be affected by, among other things, unexpected research and developed difficulties or delays; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisNovartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools and consumer health products. Novartis is the only company with leading positions in these areas. In 2009, the Group's continuing operations achieved net sales of USD 44.3 billion, while approximately USD 7.5 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit Media RelationsCentral media line : +41 61 324 2200Mariellen GallagherNovartis Institutes for BioMedical Research

+1 617 871 7665 (direct)

+1 617 909 9137 (mobile)

Jeff LockwoodNovartis Institutes for BioMedical Research

+1 617 871 7026 (direct)

+1 617 510 6997 (mobile)

jeffrey.lockwood@novartis.come-mail: For Novartis multimedia content, please visit
For questions about the site or required registration, please contact: Investor RelationsCentral phone:+41 61 324 7944Susanne Schaffert

+41 61 324 3769

North America:Pierre-Michel Bringer

+41 61 324 1065

Richard Jarvis

+1 212 830 2433+41 61 324 3018

Jill Pozarek

+1 212 830 2445Thomas Hungerbuehler

+41 61 324 8425

Edwin Valeriano

+1 212 830 2456Isabella Zinck

+41 61 324 7188e-mail:


SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
(Date:5/18/2017)... WHIPPANY, N.J. , May 17, 2017  Bayer ... growing oncology portfolio will be presented at the 53 ... Clinical Oncology (ASCO), taking place June 2-6 in ... being presented at ASCO span prostate, colorectal, liver and ... subgroup analysis from the Phase II CHRONOS-1 trial of ...
(Date:5/11/2017)... , May 11, 2017  Thornhill Research Inc. ... been awarded an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery ... the Canadian Commercial Corporation (CCC) ( Ottawa, ... Systems to administer general anesthesia to patients requiring ... "The US Marine Corps have been a ...
(Date:5/10/2017)... 10, 2017 Radiology has become the number ... have also spiraled to the number one ranking as ... than ever before as the most complete and reliable ... with lower back pain an MRI may confirm a ... pain, resulting in entirely different treatment protocols.  In these ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Manju R. Kejriwal, ... ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal understands the emotional and ... convenient, clear braces in Cincinnati, OH. Patients no longer need to feel the esthetic ...
(Date:5/24/2017)... ... May 24, 2017 , ... Myers Jackson is well known for auctioning homes ... luxury homes anywhere on the planet. The luxury home market is alive and well ... city-scapes. A quick search of “11 Spyglass Hill Auction will enlighten you on the ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a Career ... about Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). The ... time, will be presented by Captain Rommie Duckworth, LP, a career fire captain as ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... holistic pediatric dentistry options for its patients on Long Island, New York. ... physical well being, and is one of the biggest trends in dentistry today. ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... food ingredient solutions for the food and beverage industry offers Citri-Fi®, a natural ... statements during the purchasing decision process. As a result, labels need to deliver ...
Breaking Medicine News(10 mins):